Company Description
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patient populations with unmet medical needs.
The company’s technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes.
Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells.
The company’s lead product candidate, Reqorsa gene therapy (quaratusugene ozeplasmid), for the treatment of non-small and small cell lung cancer.
It is also developing diabetes gene therapy, a novel infusion process that uses an adeno-associated virus vector to deliver Pdx1 and MafA genes directly to the pancreatic duct; GPX-002 for Type 1 diabetes transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body’s immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.
It has license agreement from the University of Pittsburgh of the Commonwealth System of Higher Education (University of Pittsburgh) multiple technologies relating to the development of a gene therapy product for both Type 1 and Type 2 diabetes.
Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
| Country | United States |
| Founded | 2009 |
| IPO Date | Mar 29, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 15 |
| CEO | Ryan Confer |
Contact Details
Address: 3300 Bee Cave Road, Suite 650-227 Austin, Texas 78746 United States | |
| Phone | 877 774 4679 |
| Website | genprex.com |
Stock Details
| Ticker Symbol | GNPX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001595248 |
| CUSIP Number | 372446104 |
| ISIN Number | US3724462037 |
| Employer ID | 90-0772347 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Ryan M. Confer M.S. | President, Chief Executive Officer, Chief Financial Officer and Director |
| Dr. Mark S. Berger M.D. | Chief Medical Officer |
| David M. Schloss | Senior Vice President of Human Resources |
| Thomas C. Gallagher Esq. | Senior Vice President of Intellectual Property and Licensing |
| Dr. Suzanne Thornton-Jones Ph.D. | Senior Vice President of Regulatory Affairs and Quality |
| Dr. Jack A. Roth F.A.C.S., M.D. | Chairman of Scientific and Medical Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 24, 2025 | 8-K | Current Report |
| Jun 23, 2025 | 8-K | Current Report |
| Jun 17, 2025 | EFFECT | Notice of Effectiveness |
| Jun 17, 2025 | 424B3 | Prospectus |
| Jun 11, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jun 11, 2025 | 8-K | Current Report |
| Jun 9, 2025 | 8-K | Current Report |
| May 14, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| May 12, 2025 | 10-Q | Quarterly Report |
| May 7, 2025 | 8-K | Current Report |